Drug Trial Radar · NCT05743036
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
44
Actual
Start
Feb 27, 2023
Primary completion
Jul 16, 2024
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Conditions
- Metastatic Colorectal Cancer
Interventions
ZN-c3Drug
ZN-c3 tablet by mouth, in combination with encorafenib
EncorafenibDrug
Encorafenib capsule by mouth, in combination with ZN-c3
CetuximabDrug
Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase - Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Lead-in Day -1 to Cycle 1 Day 28
- Dose Expansion Phase - Objective response rate (ORR)Time frame: From first dose of any study intervention every 8 weeks during treatment, up to 12 months
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
Alliance for Multispecialty Research, LLC
Merriam, Kansas
University of Texas MD Anderson Cancer Center
Houston, Texas
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Hämatologie- Onkologie im Zentrum MVZ GmbH
Augsburg, Bavaria, Germany
Klinikum der Universität München Großhadern
Munich, Bavaria, Germany
Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie
Munich, Bavaria, Germany
Institut für Klinisch Onkologische Forschung
Frankfurt am Main, Hesse, Germany
DRK Kliniken Berlin - Köpenick
Berlin, State of Berlin, Germany
Clinexpert Kft. Bugat Pal Korhaz
Gyöngyös, Hungary
Semmelweis University-Department of Internal Medicine and Oncology
Budapest, Budapest, Hungary
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Campania, Italy
IRCCS Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, Italy
Istituto Europeo di Oncologia
Milan, Milano, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Milano, Italy
AOUI Verona
Verona, Veneto, Italy
Szpital Uniwersytecki w Krakowie
Krakow, Lesser Poland Voivodeship, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
Krakow, Lesser Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, Masovian Voivodeship, Poland
Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
Opole, Opole Voivodeship, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
Parc de Salut Mar - Hospital del Mar
Barcelona, Catalonia, Spain
Hospital Universitario Reina Sofia
Córdoba, Cordoba, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Madrid, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Valenciana, Comunitat, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.